Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Locteron: Final Phase IIa data

Final data from the open-label Phase IIa SELECT-1 trial in 32 treatment-naïve patients with HCV genotype

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE